RAP1A and urinary bladder cancer: To determine whether YM529 inhibits protein geranylgeranylation and/or farnesylation in bladder cancer cells as well as it blocks these events in other cancer cells, we investigated whether YM529 prevents the prenylation of Rap1A (which is activated after geranylgeranylation) and Ras (which is primarily activated after farnesylation).